Rafael Holdings, INC 10-Q quarterly reports

Rafael Holdings reports a wider net loss for the nine months ended April 30, 2026, driven by increased R&D spending, while cash reserves decrease.

Rafael Holdings reported a wider net loss for the second fiscal quarter and first half of 2026, driven by significantly increased research and development expenses primarily from its Cyclo acquisition, despite a gain from debt settlement.

Rafael Holdings, Inc. reported a wider net loss in its first fiscal quarter, driven by significantly increased research and development expenses following the acquisition of Cyclo Therapeutics and its pivotal Phase 3 clinical trial for Trappsol Cyclo.

Rafael Holdings, Inc. reported a reduced net loss for the nine months ended April 30, 2025, and significantly boosted its cash reserves by $35.3 million through a recent capital raise, as it consolidates its focus on the lead clinical program, Trappsol Cyclo, following the Cyclo merger.

Rafael Holdings' Q2 2025 results reveal a net loss, influenced by a goodwill impairment in the Infusion Technology segment and fluctuations in the fair value of its investment in Cyclo Therapeutics.

Rafael Holdings reported a net loss of $9 million for the quarter ended October 31, 2024, as it focuses on a planned merger with Cyclo Therapeutics and evaluates its existing assets.

Rafael Holdings' Q3 2024 results reflect a significant net loss due to the Cornerstone acquisition and a related in-process research and development expense, despite some gains from investments and a recovery of receivables.

Rafael Holdings reports a net income of $6.047 million for the quarter ended January 31, 2024, primarily driven by unrealized gains in its investment portfolio.